1 **Seroprevalence of SARS-CoV-2 and risk factors for infection among children in Uganda:**
2 **a serial cross-sectional study**
3

4 Irene Bagala*[1,2], Jane Frances Namuganga*[2], Patience Nayebare[2], Gloria Cuu[2], Thomas
5 Katairo[2], Isaiah Nabende[2], Samuel Gonahasa[2], Martha Nassali[2], Stephen Tukwasibwe[2], Grant
6 Dorsey[3], Joaniter Nankabirwa[1,2], Sabrina Bakeera Kitaka[1], Sarah Kiguli[1], Bryan Greenhouse[3],
7 Isaac Ssewanyana[2,4], Moses R Kamya,[1,2] Jessica Briggs[3]
8
9 *co-first authors
10
11 1 Makerere University College of Health Sciences, Kampala, Uganda
12 2 Infectious Diseases Research Collaboration, Kampala, Uganda
13 3 University of California, San Francisco, USA
14 4 Central Public Health Laboratory, Butabika, Uganda
15
16 Corresponding author: Irene Bagala [bglirene@gmail.com]

18 **Keywords:** COVID-19, SARS-CoV-2, seroprevalence, serosurvey, COVID-19 vaccination,
19 COVID-19 risk factors in children

20
21
22 **ABSTRACT (350 words max):**
23

Background:

Understanding the burden of COVID-19 infection in pediatric populations is crucial for guiding

public health interventions and policies. However, there are few age-stratified data available on

COVID-19 infection in children, including in Uganda. This study describes the seroprevalence of

SARS-CoV-2 and risk factors for infection among children across Uganda at two survey

timepoints. In addition, data are reported on COVID-19 related knowledge, attitudes, and

practices from Ugandan households, including adult vaccination status.

Methods:

Baseline cross-sectional community surveys were carried out in 12 communities from April to

May 2021 (post-Alpha wave), followed by surveys in 32 communities from November 2021 to

March 2022 during the Omicron wave. A household questionnaire was administered and blood

samples were collected to assay for presence of malaria parasites by microscopy and SARS-

CoV-2 seropositivity using a Luminex assay. Seroprevalence was estimated at the survey and

community level. Mixed-effects logistic regression models measured associations between

individual and household-level factors with SARS-CoV-2 seropositivity among children,

adjusting for household clustering.

Results:

More households reported disruptions in daily life at baseline compared to follow-up, though

economic impacts lingered. By the follow-up survey, 52.7% of eligible adults had received at

least one COVID-19 vaccine dose. Overall adjusted seroprevalence in children was higher at

follow-up compared to baseline (71.6% versus 19.2%, p < 0.001). Seroprevalence in children

ranged across communities from 6-37% in the baseline survey and 50-90% in the follow-up

survey. At baseline, children from the poorest households were more likely to be infected.

Increasing age remained the only consistent risk factor for SARS-CoV-2 seroconversion at both

timepoints.

Conclusions:

Results indicate that a larger number of children were infected during the Delta and Omicron

waves of COVID-19 compared to the Alpha wave. This study is the largest seroprevalence

survey in children in Uganda, providing evidence that most children were infected with SARS-

CoV-2 before the vaccine was widely available to pediatric populations. Pediatric infections

were vastly underreported by case counts, highlighting the importance of seroprevalence

surveys in assessing disease burden when testing and reporting rates are limited and many

cases are mild or asymptomatic.

MANUSCRIPT:

Background

The emergence of the SARS-CoV-2 virus in 2019 led to a global pandemic in 2020, with

countries around the world grappling with its impact. Uganda registered its first case of COVID-

19 in March 2020, marking the onset of the Alpha wave (1). In recognition of the potential for

COVID-19 causing significant morbidity and mortality in Uganda, the government responded by

instituting lock-down measures including the closure of schools, workplaces, border crossings,

and travel restrictions on March 18, 2020 (2).

However, as in many other sub-Saharan African nations, reported cases in Uganda were

significantly lower than initially expected (3–5). As of March 14, 2024, only 172,149 confirmed

cases have been reported in Uganda (1), numbers that are likely to be a gross under-estimation

of the true extent of the country's COVID-19 disease burden because access to confirmatory

testing for SARS-CoV-2 was not widespread and existing surveillance systems were ill-

equipped to capture all cases (6). Notably, there are few age-stratified data available to

understand the burden of COVID-19 infection in children, including in Uganda.

Understanding the true burden of COVID-19 infection in pediatric populations is

especially challenging because children are more likely to have asymptomatic or mild COVID-19

infection and may therefore be less likely to be captured by surveillance systems that rely on

case counts (7–9). Seroprevalence surveys, which capture both asymptomatic and symptomatic

infections, play a vital role in understanding the true burden of SARS-CoV-2 infection (6,10,11) .

Evidence from other seroprevalence surveys in Uganda and sub-Saharan Africa suggest high

rates of infection despite low national case counts; however, there are no published studies that

focus on seroprevalence in children (10–13). Data from seroprevalence surveys can help

policymakers assess the scale of transmission among children and inform public health

strategies.

Herein we describe the seroprevalence of SARS-CoV-2 and risk factors for infection

among children across Uganda using data from cross-sectional household surveys conducted

at two timepoints; April-May 2021 (after the Alpha wave) and November 2021-March 2022

(during the Omicron wave). In addition, these surveys also collected data on COVID-19 related

knowledge, attitudes, and practices from an adult member of the household.

Methods
94
Study sites and timeline

This COVID-19 sub-study was embedded within a cluster-randomized trial to evaluate

the impact of two types of long-lasting insecticidal bed nets (LLINs) distributed as part of

Uganda's 2020-2021 national universal coverage campaign. The parent study included 64

clusters from 32 districts (2 clusters per district). A cluster was defined as a target area

surrounding public health facilities with enhanced malaria surveillance, known as Malaria

Reference Centres (MRCs). Target areas included the village in which the MRC was located

and adjacent villages that met the following criteria: (1) did not contain another government-run

health facility, (2) located in the same sub-county as the MRC, and (3) similar incidence of

malaria as the MRC's village. All households within the MRC target areas were mapped and

enumerated to generate a sampling frame for the cross-sectional surveys. Baseline cross-

sectional community surveys were carried out in the target areas of 12 of the 64 MRCs from

April to May 2021, and follow-up surveys were carried out in the target areas of all 64 MRCs

from November 2021 to March 2022, 12 months following LLIN distribution **(Figure 1)**. For each

cluster for each survey, 50 households with at least one child aged 2-10 were randomly enrolled

from those enumerated, using criteria previously published (14).

For the cross-sectional surveys, a household questionnaire was administered to the

heads of household or other designated adult using pre-programmed tablets. Information was

gathered on characteristics of households and residents, proxy indicators of wealth including

ownership of assets, and LLIN ownership. For this sub-study, additional questions on COVID-19

attitudes, beliefs, and behaviors were added. Questions about vaccination status were asked of

the household head about every individual in the household.

Sample collection

During the baseline survey of 12 MRC target areas, a finger prick blood sample was

collected from all children in the household aged 2-10 who were present. During the follow-up

survey, sample collection was expanded, and finger prick blood samples were collected from all

children less than 18 years of age from 32 of the 64 MRC target areas. At both timepoints, blood

samples were used to prepare a thick blood smear and prepare a dried blood spot (DBS). For

both cross-sectional surveys, informed consent was obtained at the time of the evaluation

including consent for future use of biological specimens, along with assent if the child was 8

years old or older. Individual level demographic and clinical data were collected from all children

eligible for sample collection.

Laboratory Methods

To determine the presence of malaria parasites, thick blood smears were stained with

2% Giemsa for 30 min and read by experienced laboratory technologists. A thick blood smear

was considered negative when the examination of 100 high-power fields did not reveal asexual

parasites. For quality control, all slides were read by a second microscopist and discrepant

readings were settled by a third reviewer.

For serologic evaluation, serum was eluted from a 6-mm DBS punch using a previously

described method (15). To assess total IgG responses to the receptor-binding domain (RBD) of

the spike protein, a Luminex bead assay previously described for SARS-CoV-2 serologic

studies (13) was optimized for DBS samples. Samples were assayed at 1:400 dilution to

determine antibody seropositivity, with the results expressed as mean fluorescent intensity. A

standard curve using a pool of positive serum was included on each plate to normalize for plate-

to-plate variations and to infer relative antibody concentrations using a 4-parameter logistic

model (16). For negative controls, 80 DBS were used from the PRISM-2 cohort study in Tororo

District, Uganda collected in 2017 and 2018 (17). For positive controls,151 DBS were used from

volunteers enrolled in the UCSF Long-term Impact of Infection with Novel Coronavirus study

(18).

Statistical Analysis

STATA (version 17) and R (version 4.3.1) were used for data analysis. Responses to the

household survey about COVID-19 knowledge, attitudes, and behaviors were tabulated for each

survey time point as simple proportions and compared using the Chi-squared test. Survey data

were included for all 12 communities surveyed at baseline and for the 32 communities with

expanded sample collection at follow up.

To determine the cut off for seropositivity, receiver-operator curve analysis was performed using

R package ROCR (19) to maximize both sensitivity and specificity of the assay based on the

relative antibody concentration data from positive and negative controls. A sample from an

individual was determined to be seropositive if the mean fluorescent intensity was above the

cutoff. Assay sensitivity was 94.7% and specificity was 97.5%. Raw SARS-CoV-2

seroprevalence at each MRC was calculated as the number of samples that tested positive over

all samples tested from that MRC. We then calculated seroprevalence at the MRC level

adjusted for sensitivity and specificity.

Univariate and multivariate mixed-effects logistic regression models were used to measure

associations between household-level and individual-level factors with SARS-CoV-2

seropositivity among children, accounting for clustering within households. Statistical

significance was assessed using two-tailed tests with a p-value threshold of less than 0.05.

Confidence intervals for odds ratios were set at 95%.

Ethical approval

The parent (LLINEUP2, ClinicalTrials.gov: NCT04566510) study was approved by the

Institutional Review Boards (IRBs) at Makerere University School of Medicine Research and

Ethics Committee (SOMREC), the Uganda National Council for Science and Technology

(UNCST), the University of California San Francisco and London School of Hygiene and

Tropical Medicine. Informed consent, including consent for future use of biological specimens,

was obtained at enrollment. A request for waiver of consent to conduct laboratory analysis was

obtained from SOMREC. For this sub-study, laboratory analysis was only conducted on

samples for which participants had given consent for future use of biological specimens.

RESULTS

Study Profile

Figure 2 shows daily reported cases of SARS-CoV-2 at the national level; clear peaks in

reported cases are consistent with infections caused by the Alpha variant (December

2020□January 2021), the Delta variant (May□July 2021), and the Omicron variant (December

2021-February 2022) (1). Data for this study came from cross-sectional surveys performed

across Uganda in the target area of 12 MRCs from April to May 2021 (blue bar, **Figure 2**) and

the target areas of 32 MRCs from November 2021 to March 2022 (green bar, **Figure 2**).

Therefore, the baseline survey data were collected after the Alpha wave and before the surge of

the Delta wave, and the follow-up survey data was collected throughout the Omicron wave.

Details of the study participants with DBS samples collected at each survey time point are

shown in Figure 1. In the baseline survey, children ages 2-10 were eligible for sample collection,

while in the follow-up survey, all children <18 years of age were eligible for sample collection.

Serology data were successfully generated for 96.8% of eligible participants in the baseline

study and for 99.4% of eligible participants in the follow-up survey. At the baseline survey, 423

(52.3%) of the children were ages 2-5 years and 386 (47.7%) of the children aged 6-10 years.

During the follow-up survey, 561 (20.1%) of the children were aged less than 2 years, 973

(34.8%) between 2 to 5 years, 1026 (36.7%) between 6 to 10 years and 233 (8.3%) between 11

to 17 years.

COVID-19 related knowledge, attitudes, and behaviors

Table 1 presents data on knowledge, perceptions and behaviors related to COVID-19 from the

baseline and the follow-up household surveys. Avoidance of crowds, increased hand washing,

and masking outside the home were reported at very high rates (>80%) during the baseline

survey and generally remained high, though there was less hand washing reported during the

Omicron wave (**Table 1**). Knowledge about the modes of transmission of COVID-19 was also

high; > 80% of household heads reported understanding that coughing/sneezing promoted the

spread of COVID-19. Face to face talking and indirect spread through fomites were also

correctly identified as routes of transmission, though fewer households were aware of fomites

as a possible means of transmission. More households reported disruptions in daily life in the

baseline survey compared to the follow-up survey (41.3% vs 25.6%). The largest disruptions in

daily life at baseline included lost income (21.5%), restricted movement (7.6%), children being

unable to attend school (4.6%), and not visiting friends or family (3.2%). All reported disruptions

in day-to-day life improved during the follow-up survey; however, 15.8% of households still

reported a loss of income, implying that the pandemic had an economic impact still felt at the

time of the follow up survey. Compared to the baseline survey, an improvement in ability to

travel was reported in the follow-up survey (63.4% vs 49.4% reporting difficulty traveling from

baseline to follow-up). Importantly, nearly half of household heads reported health facility

medication stockouts at baseline, and 33% reported staff shortages. Both availability of

medicines and staff were improved at follow-up but rates of disrupted services remained high.

Table 1. COVID-19 related knowledge, attitudes, and behaviors

Questions	Categories	Baseline survey (n = 634)	Follow-up survey (n = 1729)
Do you avoid crowds? Do you wash your hands more often? Do you wear a mask outside the home?		539 (85.0%)	1,545 (89.4%)
		551 (86.9%)	1,280 (74.0%)
		553 (87.2%)	1,419 (82.1%)
Can COVID-19 be spread the following way?	Coughing/sneezing	514 (81.1%)	1,530 (88.5%)
	Face to face talking	415 (65.5%)	1,036 (59.9%)
	Indirect contact / fomites	128 (20.2%)	523 (30.25%)
	Doesn't know how COVID-19 is spread	23 (3.6%)	19 (1.1%)
If your daily life has been changed by COVID-19, how has it changed?	Greater food insecurity	15 (2.4%)	23 (1.3%)
	Lost income	136 (21.5%)	274 (15.8%)
	Not visiting friends or family	20 (3.2%)	11 (0.6%)
	Higher prices	4 (0.6%)	16 (0.9%)
	Children at home from school	31 (4.9%)	31 (1.8%)
	Masks required/hand washing/social distancing	9 (1.4%)	6 (0.3%)
	Movement restricted	48 (7.6%)	63 (3.6%)
	Lack of medication	0 (0%)	0 (0%)
	Fear of getting sick	11 (1.7%)	28 (1.6%)
	Can't go to church	2 (0.3%)	12 (0.7%)
Travel has been more difficult due to COVID-19 lockdowns		402 (63.4%)	854 (49.4%)

| Changes noticed regarding care available at local health facilities | No medications available | 303 (47.8%) | 455 (26.2%) 220 |
| | Less staff available | 211 (33.3%) | 221 (12.8%) |

COVID-19 Vaccination

Vaccination to prevent SARS-CoV-2 infection was not available in Uganda at the time of the

baseline survey and was not available for children during the time period of either survey (20).

Vaccination status was assessed in follow-up surveys from November 2021 to March 2022 by

asking the household head if each individual member of the household was vaccinated. 1,753

individuals out of 3,326 adults (52.7%) were reported to be vaccinated. The majority of

individuals received one dose, while 24.6% had received two doses. The most commonly

received first vaccine was the Astra-Zeneca vaccine (40.5%), followed by the Johnson and

Johnson vaccine (29.5%) and mRNA vaccines (Pfizer, Moderna, or not otherwise specified)

(17.4%) **(Supplemental Table 1)**. Astra-Zeneca remained the most commonly received second

vaccine (59.9%) followed by Sinovac/Sinopharm (18.3%).

Seroprevalence of SARS-CoV-2 in children at baseline and follow-up surveys

SARS-CoV-2 seroprevalence in children was estimated in the target areas around each MRC

for both survey timepoints **(Figure 3)**. Overall adjusted seroprevalence was higher at follow-up

compared to baseline (71.6% versus 19.2%, p < 0.001). In the baseline survey, seroprevalence

in the communities surrounding the surveyed MRCs ranged from 5.7% at Butagaya to 37.3% at

Namokora. Seroprevalence increased at all sites in the follow-up survey; the lowest

seroprevalence at follow-up was 50.0% at Kigandalo, and 9 sites had a seroprevalence >81% in

the follow-up survey, with the highest seroprevalence at Kibaale (89.6%).

Table 2. Risk factors associated with seropositivity to SARS-COV-2 among Ugandan children at baseline and follow-up surveys

Variable	Categories	Seroprevalence	OR (95% CI)	p-value	aOR (95% CI)	p-value	Seroprevalence	OR (95% CI)	p-value	aOR (95% CI)	p-value
			Baseline survey					Follow-up survey			
			Univariate analysis*		Multivariate analysis*			Univariate analysis*		Multivariate analysis*	
Individual level risk factors											
Age in years	≤ 2	--	--		--		371/561 (66.1%)	reference group		reference group	
	3-5	68/423 (16.1%)	reference group		reference group		695/973 (71.4%)	1.39 (1.05-1.85)	0.02	1.42 (1.07-1.90)	0.015
	6-10	89/386 (23.1%)	1.72 (1.13-2.64)	0.01	1.69 (1.11-2.57)	0.02	797/1026 (77.7%)	2.03 (1.52-2.72)	0.00	2.11 (1.56-2.84)	0.000
	11-17	--	--		--		190/233 (81.6%)	3.13 (1.95-5.04)	0.00	3.16 (1.96-5.09)	0.000
Gender	Male	72/401 (18.0%)	reference group		reference group		973/1340 (72.6%)	reference group		reference group	
	Female	85/408 (20.8%)	1.21 (0.81-1.81)	0.35	1.16 (0.78-1.74)	0.46	1080/1453 (74.3%)	1.16 (0.94-1.44)	0.16	1.11 (0.89-1.38)	0.34
Parasitemia by microscopy	No	115/588 (19.6%)	reference group		reference group		1579/2151 (73.4%)	reference group		reference group	
	Yes	42/220 (19.1%)	0.82 (0.60-1.5)	0.82	0.83 (0.52-1.32)	0.43	474/642 (73.8%)	1.04 (0.80-1.34)	0.79	0.89 (0.68-1.17)	0.42
Household level risk factors											
Wealth index	Least poor	36/260 (13.9%)	reference group		reference group		772/1037 (74.5%)	reference group		reference group	
	Middle	54/282 (19.2%)	1.51 (0.89-2.56)	0.125	1.55 (0.88-2.72)	0.128	652/896 (72.8%)	0.96 (0.72-1.29)	0.79	0.89 (0.65-1.22)	0.48
	Poorest	67/265 (25.3%)	2.27 (1.34-3.84)	0.002	2.51 (1.37-4.60)	0.003	629/860 (73.1%)	0.98 (0.73-1.31)	0.88	0.82 (0.57-1.17)	0.27
House construction	Modern	44/215 (20.5%)	reference group		reference group		831/1144 (72.6%)	reference group		reference group	
	Traditional	113/594 (19.0%)	0.88 (0.55-1.42)	0.62	0.61 (0.36-1.06)	0.08	1222/1649 (74.1%)	1.10 (0.86-1.41)	0.44	1.00 (0.71-1.41)	0.99
Number of residents per room used for sleeping	<2	30/185 (16.2%)	reference group		reference group		390/527 (74.0%)	reference group		reference group	
	2-3	77/399 (19.3%)	1.29 (0.75-2.23)	0.36	1.11 (0.64-1.94)	0.71	1097/1498 (73.2%)	0.96 (0.70-1.31)	0.79	1.00 (0.72-1.53)	0.99
	>3	50/225 (22.2%)	1.58 (0.86-2.90)	0.14	1.32 (0.71-2.46)	0.39	566/768 (73.7%)	1.00 (0.70-1.44)	1.00	1.05 (0.71-1.53)	0.82
Presence of windows	Uncovered windows	14/62 (22.6%)	reference group		reference group		59/92 (64.1%)	reference group		reference group	
	Covered windows	62/360 (17.2%)	0.67 (0.30-1.49)	0.32	62/360 (17.2%)	0.48	1000/1380 (72.5%)	1.50 (0.76-2.97)	0.25	1.38 (0.69-2.77)	0.36
	No windows present	81/387 (20.9%)	0.88 (0.40-1.93)	0.74	81/387 (20.9%)	0.58	994/1321 (75.3%)	1.88 (0.95-4.62)	0.07	1.97 (0.96-4.02)	0.64

Individual and household level risk factors associated with seropositivity to SARS-COV-2

among Ugandan children

Table 2 presents associations between individual and household risk factors and SARS-CoV-2 seroprevalence among children in Uganda by univariate and multivariate analysis. At baseline, older age was associated with seroconversion (aOR 1.69, CI 1.11-2.57). In addition, children in the poorest households were more likely to have seroconverted compared to those in the wealthiest households (aOR 2.51, CI 1.37 - 4.60). At follow-up, only increasing age was associated with SARS-CoV-2 seroconversion; there was no longer an association between household wealth index and seroconversion.

Gender was not associated with seroconversion at baseline or at follow up. Microscopic malaria parasitemia had no association with SARS-CoV-2 seroconversion at either survey timepoint. At the household level, there was no association between house construction type, household crowding as measured by the number of residents per room for sleeping, or type of windows and SARS-CoV-2 seroprevalence at baseline or follow up.

Discussion

Results from the study indicate a drastic increase in the SARS-CoV-2 seroprevalence in children from the baseline survey to the follow up survey, indicating that a larger proportion of children were infected by the Delta and Omicron waves of COVID-19 compared to the Alpha wave. Overall seroprevalence at the follow-up survey was 72%, showing that the majority of children had been infected by SARS-CoV-2 by early 2022. Older age was associated with increasing SARS-CoV-2 seroprevalence both at baseline and during the follow-up survey. Interestingly, in the baseline survey children from the poorest households were more likely to have been infected by SARS-CoV-2 compared to children from the wealthiest households, but this association was no longer evident later in the epidemic after additional waves of infection. In

addition, disruptions to daily life and access to medications and healthcare were more

significant earlier in the epidemic but improved over time, with the exception of lingering

economic impacts such as lost income. COVID-19 vaccination had reached over half of

surveyed adults by the time of the follow-up survey.

While there are no other published studies from Uganda on SARS-CoV-2 seroprevalence

exclusively in children, our finding of an overall seroprevalence of 72 % in a survey conducted

from November 2021-March 2022 (during the Omicron wave) is consistent with seroprevalence

studies conducted in Uganda in other age groups. A blood donor study that evaluated donors

aged 16 and over between October 2019 and April 2022 found that N and S seropositivity

increased throughout the pandemic, reaching 83% in January-April 2022 (12). A cohort study in

eastern Uganda that included both children and adults found that by the end of the Delta wave

(before widespread vaccination) 68% of the cohort had been infected, and after the Omicron

wave, 85% had been infected (13). While the seroprevalence estimate of 72% from this study is

lower than that found by the two other studies in Uganda after the Omicron wave, this might be

expected since this study was conducted during and not after the Omicron wave. In addition,

since increasing age is correlated with increasing seroprevalence, a lower seroprevalence may

be expected in a study that only includes children compared to studies including adults.

The finding that increasing age is associated with higher seroprevalence in children is in

agreement with seroprevalence studies in Uganda and elsewhere that have indicated

seroprevalence is lowest in young children (8,11–13,21–23). Higher seroprevalence with

increasing age could be due to differences in behavior, with older children more likely to attend

gatherings outside the household (24,25), immunity (26–28), or case severity (7,29,30). We

also found evidence that children from poorer households were more likely to be infected with

SARS-CoV-2 earlier in the pandemic. This is consistent with studies from other countries where

lower socioeconomic status was associated with a higher risk of infection early in the pandemic

(21,25,31). However, by the time of the follow-up survey, this association was no longer

evident, likely because the majority children had been infected. While it is possible that the

poorest children remained at higher risk and were re-infected at higher rates than children in

wealthier households, we were unable to test this hypothesis.

Survey findings indicated severe disruptions in daily life, including inability to travel and lack of

access to medications at local public health facilities. Other significant reported disruptions

included loss of income and food insecurity. These disruptions improved over time but had not

normalized to the pre-COVID era by the follow-up survey. This is consistent with findings in a

previous study in Uganda, Ghana and other low income countries that reported negative effects

on finances and food insecurity as well as limited access to medical services during the COVID-

19 pandemic (32–35). Previous studies have also reported disruptions in medical service

provision including stockouts of drugs (35) and disruptions in health service utilization (36). One

modeling study using district-level DHIS2 data from Uganda reported negative effects of

COVID-19 on utilization of health services, including outpatient attendance at public health

facilities and child health services, which were most severe early in the pandemic (37). This is in

contrast with another study by Namuganga et al. showing no major effects on the total number

of visits to 17 sentinel malaria surveillance outpatient health facilities in the first year after the

COVID-19 pandemic (2). Most studies that do report disruptions due to the COVID-19

pandemic report the highest effect in the earliest months of the pandemic, consistent with the

trend seen in this study and with the timing of the strictest lockdown policies in Uganda.

Our study is the largest seroprevalence survey in children in Uganda, providing evidence that

most children were infected with SARS-CoV-2 before the vaccine was available to pediatric

populations. Though only 12 districts were included in the baseline survey, data was available

from 32 districts in the follow-up survey, providing good geographic representation of most

regions in Uganda except for the southwest. A limitation is that SARS-CoV-2 seroprevalence

may have been underestimated in this study because SARS-CoV-2 antibodies wane over time,

particularly in asymptomatic or mild infection (38,39). In addition, most study sites were rural,

and therefore some more urban areas such as Wakiso District and Kampala that registered

higher numbers of SARS-CoV-2 cases (due to higher transmission or better access to testing)

during pandemic waves were not represented in this survey. This would also likely bias our

seroprevalence estimate toward underestimation. Our study highlights the usefulness of

seroprevalence surveys to estimate the true burden of infection, especially in rural populations

with less access to molecular testing for SARS-CoV-2 where using case reports alone would

severely underestimate the burden of SARS-CoV-2 infection in children.

Conclusions

In summary, SARS-CoV-2 seroprevalence among children in Uganda was high by early 2022,

providing evidence that the majority of children in Uganda were infected before the availability of

pediatric vaccination. Assessment of risk factors associated with SARS-CoV-2 infection

revealed increasing risk with increasing age, and higher risk in poorer children. These findings

may be useful to direct public health preventative strategies to protect vulnerable pediatric

populations in the next global pandemic. In addition, because COVID-19 disease in children is

often asymptomatic or mild and molecular testing for infection was not easily accessible, case

reports of infection in children vastly underrepresented the true infection rate in children in

Uganda. Seroprevalence surveys remain an important way of assessing the true burden of

disease when testing and reporting rates are not readily available.

348
349
350
351

FIGURE AND TABLE TITLES AND LEGENDS:

Figure 1. Timing of the baseline (blue) and follow-up (green) cross-sectional surveys.

Figure 2: Study profile of participants enrolled in the study

Table 1. COVID-19 related knowledge, attitudes, and behaviors

Figure 3. SARS-CoV-2 seroprevalence in the target areas surrounding MRCs in the

baseline and follow-up cross-sectional surveys.

A. RBD seroprevalence in children ages 2-10 in the baseline survey. **B.** RBD seroprevalence in

children 0-17 in the follow-up survey.

Table 2. Risk factors associated with seropositivity to SARS-COV-2 among Ugandan

children at baseline and follow-up surveys

DECLARATIONS

Ethical approval and consent to participate

All methods were carried out in accordance with relevant guidelines and regulations including

the Declaration of Helsinki. Study procedures were approved by Institutional Review Boards

(IRBs) at Makerere University School of Medicine Research and Ethics Committee (SOMREC),

the Uganda National Council for Science and Technology (UNCST), the University of California

San Francisco and London School of Hygiene and Tropical Medicine. A request for waiver of

consent to conduct laboratory analysis was obtained from SOMREC. Furthermore, informed

consent was obtained from all subjects in this manuscript as stated in the methods (lines 124-

125).

Author Contributions

IB, JFN, and JB drafted the manuscript; IB, JFN, BG, JB, ST, and IS conceived the idea; JB and

IB performed the analysis; PN, GC, TK and ST performed laboratory assays; the LLINEUP2

study staff (SG, MN, JFN and IN) performed the cross-sectional surveys; BG, IS, JB, MK, JN

and GD obtained funding; JB, IS, MK, SK, SBK, and JN provided supervision over study staff,

laboratory work, and analysis; everyone reviewed the manuscript and edited.

Funding

We acknowledge sources of funding support including Makerere University Research and

Innovations Fund (MAKRIF/DVCFA/026/20) (IB, JFN, JN, MK, PN, IN); Fogarty International

Center of the National Institutes of Health (D43TW010526) (IB, JFN, GC, PN, TK, SG, MN, Dr.

ST); the Bill and Melinda Gates Foundation, INV-017893 and INV-023690 (JB, IS, BG); and

NIH/NIAID (K23 AI166009) to JB.

Competing Interest Declaration

The authors have no competing interests.

401
402

REFERENCES

1. World Health Organization. Coronavirus (COVID-19) Dashboard, Uganda [Internet]. [cited 2024 Mar 14]. Available from: https://covid19.who.int/region/afro/country/ug

2. Namuganga JF, Briggs J, Roh ME, Okiring J, Kisambira Y, Sserwanga A, et al. Impact of COVID-19 on routine malaria indicators in rural Uganda: an interrupted time series analysis. Malar J. 2021 Dec 20;20(1):1–11.

3. Massinga Loembé M, Tshangela A, Salyer SJ, Varma JK, Ouma AEO, Nkengasong JN. COVID-19 in Africa: the spread and response. Nat Med. 2020 Jul;26(7):999–1003.

4. Salyer SJ, Maeda J, Sembuche S, Kebede Y, Tshangela A, Moussif M, et al. The first and second waves of the COVID-19 pandemic in Africa: a cross-sectional study. Lancet. 2021;397(10281):1265.

5. Bamgboye EL, Omiye JA, Afolaranmi OJ, Davids MR, Tannor EK, Wadee S, et al. COVID-19 Pandemic: Is Africa Different? J Natl Med Assoc. 2021 Jun;113(3):324–35.

6. Tessema SK, Nkengasong JN. Understanding COVID-19 in Africa. Nat Rev Immunol. 2021;21(8):469.

7. Lu X, Zhang L, Du H, Zhang J, Li YY, Qu J, et al. SARS-CoV-2 Infection in Children. N Engl J Med. 2020 Apr 23;382(17):1663–5.

8. Viner RM, Mytton OT, Bonell C, Melendez-Torres GJ, Ward J, Hudson L, et al. Susceptibility to SARS-CoV-2 Infection Among Children and Adolescents Compared With Adults: A Systematic Review and Meta-analysis. JAMA Pediatr. 2021 Feb 1;175(2):143–56.

9. Li J, Thoon KC, Chong CY, Maiwald M, Kam KQ, Nadua K, et al. Comparative analysis of symptomatic and asymptomatic SARS-CoV-2 infection in children. Ann Acad Med Singapore. 2020 Aug;49(8):530–7.

10. Chisale MRO, Ramazanu S, Mwale SE, Kumwenda P, Chipeta M, Kaminga AC, et al. Seroprevalence of anti-SARS-CoV-2 antibodies in Africa: A systematic review and meta-analysis. Rev Med Virol. 2022 Mar;32(2):e2271.

11. Naeimi R, Sepidarkish M, Mollalo A, Parsa H, Mahjour S, Safarpour F, et al. SARS-CoV-2 seroprevalence in children worldwide: A systematic review and meta-analysis. EClinicalMedicine. 2023 Feb;56:101786.

12. Bloch EM, Kyeyune D, White JL, Ddungu H, Ashokkumar S, Habtehyimer F, et al. SARS-CoV-2 seroprevalence among blood donors in Uganda: 2019–2022. Transfusion . 2023 Jul 1;63(7):1354–65.

13. Briggs J, Takahashi S, Nayebare P, Cuu G, Rek J, Zedi M, et al. Seroprevalence of Antibodies to SARS-CoV-2 in Rural Households in Eastern Uganda, 2020-2022. JAMA Netw Open. 2023 Feb 1;6(2):e2255978.

14. Okiring J, Gonahasa S, Nassali M, Namuganga JF, Bagala I, Maiteki⍰Sebuguzi C, et al.

440 LLIN Evaluation in Uganda Project (LLINEUP2)—Factors associated with coverage and
441 use of long‑lasting insecticidal nets following the 2020–21 national mass distribution
442 campaign: a cross-sectional survey of 12 districts. Malar J. 2022 Oct 19;21(1):1–12.

443 15. Wu L, Hall T, Ssewanyana I, Oulton T, Patterson C, Vasileva H, et al. Optimisation and
444 standardisation of a multiplex immunoassay of diverse Plasmodium falciparum antigens to
445 assess changes in malaria transmission using sero-epidemiology. Wellcome Open
446 Research [Internet]. 2019 [cited 2023 Nov 12];4. Available from:
447 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7255915/

448 16. Website [Internet]. Available from: Github. Flexfit: flexible format standard curve fitting and
449 data processing (R Package). Accessed July 31, 2022.
450 https://github.com/EPPIcenter/flexfit

451 17. Nankabirwa JI, Bousema T, Blanken SL, Rek J, Arinaitwe E, Greenhouse B, et al.
452 Measures of malaria transmission, infection, and disease in an area bordering two districts
453 with and without sustained indoor residual spraying of insecticide in Uganda. PLoS One
454 [Internet]. 2022 Dec 30 [cited 2024 Apr 28];17(12). Available from:
455 https://pubmed.ncbi.nlm.nih.gov/36584122/

456 18. Peluso MJ, Takahashi S, Hakim J, Kelly JD, Torres L, Iyer NS, et al. SARS-CoV-2 antibody
457 magnitude and detectability are driven by disease severity, timing, and assay. Sci Adv
458 [Internet]. 2021 Jul;7(31). Available from: http://dx.doi.org/10.1126/sciadv.abh3409

459 19. Website [Internet]. Available from: Sing T, Sander O, Beerenwinkel N, Lengauer T (2005).
460 "ROCR: visualizing classifier performance in R." Bioinformatics, 21(20), 7881.
461 http://rocr.bioinf.mpi-sb.mpg.de.

462 20. Ministry of Health | Government of Uganda [Internet]. 2021 [cited 2024 Mar 31]. Update on
463 covid-19 vaccination in Uganda - Ministry of Health. Available from:
464 https://www.health.go.ug/cause/update-on-covid-19-vaccination-in-uganda/

465 21. Sebastian T, Carlson JJ, Gaensbauer J, Podewils LJ. Epidemiology and Transmission
466 Dynamics of COVID-19 in an Urban Pediatric US Population. Public Health Rep. 2022 Jul
467 4;137(5):1013–22.

468 22. Misra P, Kant S, Guleria R, Rai SK, Kishore S, Baidya S, et al. Serological prevalence of
469 SARS-CoV-2 antibody among children and young age group (between 2 and 17 years) in
470 India: An interim result from a large multicentric population-based seroepidemiological
471 study. Journal of Family Medicine and Primary Care. 2022 Jun;11(6):2816.

472 23. Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-
473 POP): a population-based study. Lancet. 2020 Aug 1;396(10247):313–9.

474 24. Hobbs CV. Factors Associated with Positive SARS-CoV-2 Test Results in Outpatient
475 Health Facilities and Emergency Departments Among Children and Adolescents Aged 18
476 Years — Mississippi, September–November 2020. MMWR Morb Mortal Wkly Rep
477 [Internet]. 2020 [cited 2024 Mar 15];69. Available from:
478 https://www.cdc.gov/mmwr/volumes/69/wr/mm6950e3.htm

479 25. Reicher S, Ratzon R, Ben-Sahar S, Hermoni-Alon S, Mossinson D, Shenhar Y, et al.

Nationwide seroprevalence of antibodies against SARS-CoV-2 in Israel. Eur J Epidemiol.
2021;36(7):727.

26. Rotulo GA, Palma P. Understanding COVID-19 in children: immune determinants and post-
infection conditions. Pediatr Res. 2023 Mar 6;94(2):434–42.

27. Yoshida M, Worlock KB, Huang N, Lindeboom RGH, Butler CR, Kumasaka N, et al. Local
and systemic responses to SARS-CoV-2 infection in children and adults. Nature.
2022;602(7896):321.

28. Weisberg SP, Connors TJ, Zhu Y, Baldwin MR, Lin WH, Wontakal S, et al. Distinct
antibody responses to SARS-CoV-2 in children and adults across the COVID-19 clinical
spectrum. Nat Immunol. 2021 Jan;22(1):25.

29. Ludvigsson JF. Systematic review of COVID-19 in children shows milder cases and a
better prognosis than adults. Acta Paediatr. 2020 Jun;109(6):1088–95.

30. She J, Liu L, Liu W. COVID-19 epidemic: Disease characteristics in children. J Med Virol.
2020 Jul;92(7):747–54.

31. O'Neill B, Kalia S, Hum S, Gill P, Greiver M, Kirubarajan A, et al. Socioeconomic and
immigration status and COVID-19 testing in Toronto, Ontario: retrospective cross-sectional
study. BMC Public Health [Internet]. 2022 May 29 [cited 2024 Mar 11];22(1). Available
from: https://pubmed.ncbi.nlm.nih.gov/35643450/

32. Pattnaik J, Jalongo MR. The Impact of COVID-19 on Early Childhood Education and Care:
International Perspectives, Challenges, and Responses. Springer Nature; 2022. 505 p.

33. Nuwematsiko R, Nabiryo M, Bomboka JB, Nalinya S, Musoke D, Okello D, et al.
Unintended socio-economic and health consequences of COVID-19 among slum dwellers
in Kampala, Uganda. BMC Public Health. 2022 Jan 13;22(1):88.

34. Josephson A, Kilic T, Michler JD. Socioeconomic impacts of COVID-19 in low-income
countries. Nat Hum Behav. 2021 May;5(5):557–65.

35. Kabwama SN, Wanyenze RK, Kiwanuka SN, Namale A, Ndejjo R, Monje F, et al.
Interventions for Maintenance of Essential Health Service Delivery during the COVID-19
Response in Uganda, between March 2020 and April 2021. Int J Environ Res Public Health
[Internet]. 2022 Sep 30;19(19). Available from: http://dx.doi.org/10.3390/ijerph191912522

36. Andia-Biraro I, Baluku JB, Olum R, Bongomin F, Kyazze AP, Ninsiima S, et al. Effect of
COVID-19 pandemic on inpatient service utilization and patient outcomes in Uganda. Sci
Rep. 2023 Jun 15;13(1):9693.

37. Angeles G, Silverstein H, Ahsan KZ, Kibria MG, Rakib NA, Escudero G, et al. Estimating
the effects of COVID-19 on essential health services utilization in Uganda and Bangladesh
using data from routine health information systems. Front Public Health. 2023 Sep
27;11:1129581.

38. Khaitan A, Datta D, Bond C, Goings M, Co K, Odhiambo EO, et al. Level and Duration of
IgG and Neutralizing Antibodies to SARS-CoV-2 in Children with Symptomatic or

Asymptomatic SARS-CoV-2 Infection. Immunohorizons. 2022 Jun 1;6(6):408–15.

39. Javier Ibarrondo F, Fulcher JA, Goodman-Meza D, Elliott J, Hofmann C, Hausner MA, et
al. Rapid Decay of Anti–SARS-CoV-2 Antibodies in Persons with Mild Covid-19. N Engl J
Med [Internet]. 2020 Jul 21 [cited 2024 Mar 15]; Available from:
https://www.nejm.org/doi/full/10.1056/nejmc2025179

RBD seroprevalence at baseline survey
- 0-10%
- 11-20%
- 21-30%
- 31-40%
- Waterbodies
- Districts

RBD seroprevalence at follow-up survey
- 51-60%
- 61-70%
- 71-80%
- 81-90%
- Waterbodies
- Districts